Subscribe to our Newsletters !!
The nipah virus (NiV), a zoonotic virus, can infec
Test tubes are kept in a test tube holder. When th
The male reproductive system ejaculates semen, a t
Participants in clinical trials are volunteers hel
Extrasensory perception (ESP) is perception that o
Fermentation definition: fermentation is an anaero
The field of drug analysis encompasses various com
Mumbai, India; April 30, 2019: – Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce receipt of final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan Tablets 5mg & 10mg from the United States Food and Drug Administration (US FDA).
Cipla’s Ambrisentan Tablets 5mg & 10mg is AB-rated generic therapeutic equivalent version of Gilead Sciences, Inc’s Letairis®. Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening.
The U.S. Sales of Letairis® Tablets USP stood at $943 million in 2018. The product is available for shipping immediately.